Alcobra (ADHD) Reports Q1 Loss of $0.57

Alcobra (Nasdaq: ADHD) reported Q1 EPS of ($0.57), versus ($0.05) reported last year.

"In the first quarter and recent weeks, we achieved a number of important milestones related to our development of MDX for various cognitive disorders including ADHD and Fragile X Syndrome," said Dr. Yaron Daniely, President and CEO of Alcobra. "We have also strengthened our leadership team with the appointments of Howie Rosen as Chairman of the Board, David Baker as Chief Commercial Officer and Dr. Tomer Berkovitz as Chief Financial Officer. As we have indicated, expenses have increased due to our aggressive efforts on executing and achieving our clinical development milestones. We are on track to report multiple data readouts in the second half of 2014 including clinical data from our Phase III adult ADHD study, our Phase II pediatric ADHD study, and our Phase II study in adolescents and adults with Fragile X Syndrome."

For earnings history and earnings-related data on Alcobra (ADHD) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c
• Laird Superfood, Inc. (LSF) Misses Q2 EPS by 22c ; Offers Guidance